Eli Lilly and Company's new $5 billion facility in Goochland County, Virginia will be the company's first fully integrated site built specifically for its antibody-drug conjugate and bioconjugate portfolio.[1] Roche's $50 billion US investment includes a gene therapy facility in Pennsylvania the company is calling a center of excellence.[2] [3] AstraZeneca's own $50 billion commitment includes new cell therapy manufacturing facilities in Rockville, Maryland and Tarzana, California.[4]
Three of the largest pharma companies in the world are pouring capital into advanced therapy manufacturing at the same time, and all three are will be pulling from the same scarce talent pool once the buildings are finished.
Cytiva's 2025 Global Biopharma Index surveyed 1,250 industry leaders and found that more than a third reported severe or critical workforce shortages specifically in supporting emerging modalities like cell and gene therapy.[5] Separately, roundtable discussions hosted by the ISCT, International Society for Cell & Gene Therapy identified manufacturing and process development as the single biggest workforce gap in the sector,[6] ahead of research, regulatory, and commercial roles combined. This isn't a general life sciences hiring problem. It's concentrated in a specific set of functions that most conventional pharma manufacturing sites have never needed to staff before.
Taking a therapy that works in a lab and making it work reliably under GMP conditions, at commercial scale, is a distinct skill from either research science or traditional manufacturing engineering. It requires understanding tech transfer, scale-up, and comparability testing for products that behave nothing like a small molecule or even a conventional biologic. Few people currently in the industry have done this more than a handful of times, because the industry itself has only had commercial-scale cell and gene therapy products to work with for a few years.
GMP manufacturing sits alongside it as an equally acute gap. Autologous cell therapy production, where a patient's own cells are collected, modified, and returned as a single unrepeatable batch, cannot absorb the kind of variability a conventional biologics line is built to handle. There is no separate quality run to fall back on if something goes wrong midway through. The FDA approved the first two CAR-T therapies in 2017 [7], and there are seven CAR-T therapies approved for clinical use in the US today.[8] That means the people with genuine hands-on commercial manufacturing experience in this modality have mostly built that experience within the last decade, at a small number of facilities, because there simply wasn't anywhere else to get it.
Quality functions face a version of the same problem. Testing a cell or gene therapy for potency, purity, and identity requires assays built for living, patient-specific products rather than standardized chemical compounds. A quality scientist who has spent a career validating conventional biologics assays is not automatically equipped to build and validate one for an autologous product where the starting material is different every time. The skill exists. It's just concentrated in far fewer people than the roles it most resembles on an org chart.
Regulatory and CMC expertise rounds this out. Advanced therapies are reviewed and approved through pathways that differ meaningfully from conventional drug approval, and writing a CMC package that satisfies a regulator evaluating a gene or cell therapy for the first time takes people who understand how that regulator actually thinks about this modality, not just regulatory affairs experience in general. That expertise is still rare enough that companies are often competing for the same handful of people who have taken a CGT product through approval before.
None of these gaps are solved by the standard playbook that has worked for conventional pharma manufacturing hiring. Posting a role and building from a general biologics or pharma manufacturing candidate pool assumes the skills transfer cleanly, and largely they don't. The relevant experience sits with a genuinely small number of people, most of whom are not actively looking, because their skills are already in demand from the same handful of companies building this capacity right now.
That's the real constraint behind these announcements. Eli Lilly, Roche, and AstraZeneca aren't just building cleanrooms and process suites. They're each trying to staff process development, GMP manufacturing, quality, and regulatory functions that draw from the same narrow, still-maturing talent pool, at the same time, with the same urgency. The company that finds and secures that talent first will be the one whose facility actually produces a validated therapy on schedule. The one that treats hiring as an afterthought to construction will be the one explaining a delay that had nothing to do with the building.
A $5 billion facility and a $50 billion investment plan both describe capital committed. Getting a working cell or gene therapy through that facility depends on whether the specific people who know how to manufacture it were found in time.
Thor has worked inside this industry since 2012. Over that time we've placed hundreds of professionals into facilities like these, across controls, DCS, PLC, SCADA, and MES engineering, automation, project management, and data analytics, along with leadership hires at VP and director level. That's the range this kind of build actually needs, from the engineers writing the code that runs a single bioreactor to the director who has to answer for whether the whole facility hits its validation timeline. We've spent over a decade learning where that talent actually sits and how to reach the people who aren't posting their resume anywhere.
If your team is building process development, manufacturing, quality, or regulatory capability for cell and gene therapy specifically, we can help you find people who already know this work.
